The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.w

Multiple organ dysfunction/failure (MODS/MOF)

Publications

Charles J, Giovannini D, Terzi N, Schwebel C, Sturm N, Masson D, Leccia MT, Cahn JY, Manches O, Bulabois CE, Chaperot L

Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation.

Experimental hematology & oncology 2019;8;8 — 2019 — 8

Supakornnumporn S, Katirji B

Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.

Journal of clinical neuromuscular disease 2017 Dec;19;80-83 — 2017 Dec — 80-83

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

The New England journal of medicine 2017 06 22;376;2415-2426 — 2017 06 22 — 2415-2426